title: Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab).
authors.affiliation: Department of Hematology, Peking Union Medical College Hospital, No.9 Dongdansantiao, Dongcheng District, Beijing, China.
authors.forename: Kaini
authors.initials: K
authors.lastname: Shen
authors.affiliation: Department of Dermatology, Peking Union Medical College Hospital, Beijing, China.
authors.forename: Yuehua
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Hematology, Peking Union Medical College Hospital, No.9 Dongdansantiao, Dongcheng District, Beijing, China.
authors.forename: Xinxin
authors.initials: X
authors.lastname: Cao
authors.affiliation: Department of Hematology, Peking Union Medical College Hospital, No.9 Dongdansantiao, Dongcheng District, Beijing, China.
authors.forename: Daobin
authors.initials: D
authors.lastname: Zhou
authors.affiliation: Department of Hematology, Peking Union Medical College Hospital, No.9 Dongdansantiao, Dongcheng District, Beijing, China. lijian@pumch.cn.
authors.forename: Jian
authors.initials: J
authors.lastname: Li
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab